National Bank of Canada FI Purchases New Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

National Bank of Canada FI purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 59,400 shares of the specialty pharmaceutical company's stock, valued at approximately $1,855,000. National Bank of Canada FI owned approximately 0.18% of Collegium Pharmaceutical as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SummerHaven Investment Management LLC raised its position in shares of Collegium Pharmaceutical by 1.1% in the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company's stock valued at $1,048,000 after purchasing an additional 368 shares in the last quarter. Illinois Municipal Retirement Fund raised its position in shares of Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company's stock valued at $612,000 after purchasing an additional 411 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Collegium Pharmaceutical by 0.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company's stock valued at $1,718,000 after purchasing an additional 585 shares in the last quarter. Swiss National Bank increased its holdings in shares of Collegium Pharmaceutical by 1.1% in the 3rd quarter. Swiss National Bank now owns 76,100 shares of the specialty pharmaceutical company's stock valued at $1,701,000 after acquiring an additional 800 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Collegium Pharmaceutical by 5.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,713 shares of the specialty pharmaceutical company's stock valued at $514,000 after acquiring an additional 868 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on COLL. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 1st. Truist Financial boosted their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a "buy" rating in a report on Monday, February 26th. Needham & Company LLC downgraded Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a report on Friday. Finally, Piper Sandler downgraded Collegium Pharmaceutical from an "overweight" rating to a "neutral" rating and set a $39.00 price target for the company. in a report on Friday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of "Hold" and a consensus price target of $39.00.

Collegium Pharmaceutical Price Performance

NASDAQ COLL traded up $1.14 on Tuesday, reaching $33.29. The company's stock had a trading volume of 732,658 shares, compared to its average volume of 443,618. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The firm's 50 day moving average is $37.42 and its two-hundred day moving average is $32.50. Collegium Pharmaceutical, Inc. has a twelve month low of $20.83 and a twelve month high of $40.95. The stock has a market cap of $1.09 billion, a PE ratio of 13.87 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.25. The firm had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. As a group, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.